Eesti - eesti - Ravimiamet

the mentholatum company (ireland) limited - ibuprofeen+levomentool - geel - 50mg+30mg 1g 30g 1tk; 50mg+30mg 1g 15g 1tk; 50mg+30mg 1g 50g 1tk

Eesti - eesti - Ravimiamet

the simple pharma company limited - testosteroon - transdermaalne geel - 20mg 1g 85.5g 1tk

Eesti - eesti - Ravimiamet

piramal critical care b.v. - isofluraan - inhalatsiooniaur, vedelik - 1000mg 1g 100ml 1tk; 1000mg 1g 250ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belimumab - erütematoosne luupus, süsteemne - immunosupressandid - benlysta on näidustatud add-ravi patsientidel vanuses 5 aastat ja vanemad, aktiivne, autoantibody positiivne süsteemne erütematoosne luupus (sle) suure tõenäosusega haiguse tegevus (e. positiivseid anti dsdna ja väike täiendus) vaatamata standardi ravi. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Euroopa Liit - eesti - EMA (European Medicines Agency)

merck sharp dohme limited - lamivudine, raltegravir kaaliumi - hiv-nakkused - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - dutrebise on näidustatud kombinatsioonis teiste anti‑retroviral ravimitega inimese immuunpuudulikkuse viiruse (hiv‑1) infektsiooniga täiskasvanutel, noorukitel ja lastel alates 6 aastat ja kehakaaluga vähemalt 30 kg ilma praegu või varem anamneesis viirusevastaste ravimite insti (integraasi ülekande inhibiitorite) ja nrti (nukleosiidi pöördtranskriptaasi inhibiitorite) suhtes (vt lõigud 4 klassid. 2, 4. 4 ja 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - darunaviiri - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Euroopa Liit - eesti - EMA (European Medicines Agency)

piramal critical care b.v. - miglustaat - gaucheri tõbi - muud alimentary seedetrakti ja ainevahetust tooted, - yargesa on näidustatud suukaudse ravi täiskasvanud patsientidel, kellel on kerge kuni mõõdukas 1. tüüpi gaucher haiguse. yargesa võib kasutada ainult nende patsientide raviks, kellele ensüümi asendamine ravi ei sobi. yargesa on näidustatud ravi järk-järgulise neuroloogiliste sümptomite täiskasvanud patsientidel ja lastel patsientidel niemann-pick c-tüüpi haigus.

Eesti - eesti - Ravimiamet

zentiva k.s. - darunaviir - õhukese polümeerikattega tablett - 600mg 180tk; 600mg 60tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - darunaviir - õhukese polümeerikattega tablett - 800mg 120tk; 800mg 30tk; 800mg 240tk; 800mg 60tk; 800mg 90tk; 800mg 10tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - darunaviir - õhukese polümeerikattega tablett - 75mg 90tk; 75mg 480tk; 75mg 120tk; 75mg 30tk; 75mg 60tk; 75mg 10tk